Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 10/2016

01-10-2016 | Review

Aberrant expression and functions of protocadherins in human malignant tumors

Authors: Ming Shan, Yonghui Su, Wenli Kang, Ruixin Gao, Xiaobo Li, Guoqiang Zhang

Published in: Tumor Biology | Issue 10/2016

Login to get access

Abstract

Protocadherins (PCDHs) are a group of transmembrane proteins belonging to the cadherin superfamily and are subdivided into “clustered” and “non-clustered” groups. PCDHs vary in both structure and interaction partners and thus regulate multiple biological responses in complex and versatile patterns. Previous researches showed that PCDHs regulated the development of brain and were involved in some neuronal diseases. Recently, studies have revealed aberrant expression of PCDHs in various human malignant tumors. The down-regulation or absence of PCDHs in malignant cells has been associated with cancer progression. Further researches suggest that PCDHs may play major functions as tumor suppressor by inhibiting the proliferation and metastasis of cancer cells. In this review, we focus on the altered expression of PCDHs and their roles in the development of cancer progression. We also discuss the potential mechanisms, by which PCDHs are aberrantly expressed, and its implications in regulating cancers.
Literature
1.
Takeichi M. Dynamic contacts: rearranging adherens junctions to drive epithelial remodelling. Nat Rev Mol Cell Biol. 2014;15:397–410.PubMedCrossRef
2.
Suzuki ST. Protocadherins and diversity of the cadherin superfamily. J Cell Sci. 1996;109(Pt 11):2609–11.PubMed
3.
Sano K, Tanihara H, Heimark RL, Obata S, Davidson M, St JT, et al. Protocadherins: a large family of cadherin-related molecules in central nervous system. EMBO J. 1993;12:2249–56.PubMedPubMedCentral
4.
5.
Hulpiau P, van Roy F. Molecular evolution of the cadherin superfamily. Int J Biochem Cell Biol. 2009;41:349–69.PubMedCrossRef
6.
Boggon TJ, Murray J, Chappuis-Flament S, Wong E, Gumbiner BM, Shapiro L. C-cadherin ectodomain structure and implications for cell adhesion mechanisms. Science. 2002;296:1308–13.PubMedCrossRef
7.
Patel SD, Chen CP, Bahna F, Honig B, Shapiro L. Cadherin-mediated cell-cell adhesion: sticking together as a family. Curr Opin Struct Biol. 2003;13:690–8.PubMedCrossRef
8.
Morishita H, Umitsu M, Murata Y, Shibata N, Udaka K, Higuchi Y, et al. Structure of the cadherin-related neuronal receptor/protocadherin-alpha first extracellular cadherin domain reveals diversity across cadherin families. J Biol Chem. 2006;281:33650–63.PubMedCrossRef
9.
Morishita H, Yagi T. Protocadherin family: diversity, structure, and function. Curr Opin Cell Biol. 2007;19:584–92.PubMedCrossRef
10.
Kim SY, Yasuda S, Tanaka H, Yamagata K, Kim H. Non-clustered protocadherin. Cell Adhes Migr. 2011;5:97–105.CrossRef
11.
Takagi J. Structural basis for ligand recognition by RGD (Arg-Gly-Asp)-dependent integrins. Biochem Soc Trans. 2004;32:403–6.PubMedCrossRef
12.
Mutoh T, Hamada S, Senzaki K, Murata Y, Yagi T. Cadherin-related neuronal receptor 1 (CNR1) has cell adhesion activity with beta1 integrin mediated through the RGD site of CNR1. Exp Cell Res. 2004;294:494–508.PubMedCrossRef
13.
14.
Ribich S, Tasic B, Maniatis T. Identification of long-range regulatory elements in the protocadherin-alpha gene cluster. Proc Natl Acad Sci U S A. 2006;103:19719–24.PubMedPubMedCentralCrossRef
15.
Tasic B, Nabholz CE, Baldwin KK, Kim Y, Rueckert EH, Ribich SA, et al. Promoter choice determines splice site selection in protocadherin alpha and gamma pre-mRNA splicing. Mol Cell. 2002;10:21–33.PubMedCrossRef
16.
Kaneko R, Kato H, Kawamura Y, Esumi S, Hirayama T, Hirabayashi T, et al. Allelic gene regulation of Pcdh-alpha and Pcdh-gamma clusters involving both monoallelic and biallelic expression in single Purkinje cells. J Biol Chem. 2006;281:30551–60.PubMedCrossRef
17.
Hirano K, Kaneko R, Izawa T, Kawaguchi M, Kitsukawa T, Yagi T. Single-neuron diversity generated by Protocadherin-beta cluster in mouse central and peripheral nervous systems. Front Mol Neurosci. 2012;5:90.PubMedPubMedCentralCrossRef
18.
Esumi S, Kakazu N, Taguchi Y, Hirayama T, Sasaki A, Hirabayashi T, et al. Monoallelic yet combinatorial expression of variable exons of the protocadherin-alpha gene cluster in single neurons. Nat Genet. 2005;37:171–6.PubMedCrossRef
19.
Zipursky SL, Sanes JR. Chemoaffinity revisited: dscams, protocadherins, and neural circuit assembly. Cell. 2010;143:343–53.PubMedCrossRef
20.
Lefebvre JL, Kostadinov D, Chen WV, Maniatis T, Sanes JR. Protocadherins mediate dendritic self-avoidance in the mammalian nervous system. Nature. 2012;488:517–21.PubMedPubMedCentralCrossRef
21.
Wu Q, Maniatis T. A striking organization of a large family of human neural cadherin-like cell adhesion genes. Cell. 1999;97:779–90.PubMedCrossRef
22.
Hayashi S, Takeichi M. Emerging roles of protocadherins: from self-avoidance to enhancement of motility. J Cell Sci 2015.
23.
Rubinstein R, Thu CA, Goodman KM, Wolcott HN, Bahna F, Mannepalli S, et al. Molecular logic of neuronal self-recognition through protocadherin domain interactions. Cell. 2015;163:629–42.PubMedPubMedCentralCrossRef
24.
Thu CA, Chen WV, Rubinstein R, Chevee M, Wolcott HN, Felsovalyi KO, et al. Single-cell identity generated by combinatorial homophilic interactions between alpha, beta, and gamma protocadherins. Cell. 2014;158:1045–59.PubMedPubMedCentralCrossRef
25.
Hirayama T, Yagi T. Clustered protocadherins and neuronal diversity. Prog Mol Biol Transl Sci. 2013;116:145–67.PubMedCrossRef
26.
Wu Q, Zhang T, Cheng JF, Kim Y, Grimwood J, Schmutz J, et al. Comparative DNA sequence analysis of mouse and human protocadherin gene clusters. Genome Res. 2001;11:389–404.PubMedPubMedCentralCrossRef
27.
Golan-Mashiach M, Grunspan M, Emmanuel R, Gibbs-Bar L, Dikstein R, Shapiro E. Identification of CTCF as a master regulator of the clustered protocadherin genes. Nucleic Acids Res. 2012;40:3378–91.PubMedCrossRef
28.
Yokota S, Hirayama T, Hirano K, Kaneko R, Toyoda S, Kawamura Y, et al. Identification of the cluster control region for the protocadherin-beta genes located beyond the protocadherin-gamma cluster. J Biol Chem. 2011;286:31885–95.PubMedPubMedCentralCrossRef
29.
30.
Hirayama T, Tarusawa E, Yoshimura Y, Galjart N, Yagi T. CTCF is required for neural development and stochastic expression of clustered Pcdh genes in neurons. Cell Rep. 2012;2:345–57.PubMedCrossRef
31.
Victoria-Acosta G, Vazquez-Santillan K, Jimenez-Hernandez L, Munoz-Galindo L, Maldonado V, Martinez-Ruiz GU, et al. Epigenetic silencing of the XAF1 gene is mediated by the loss of CTCF binding. Sci Rep. 2015;5:14838.PubMedPubMedCentralCrossRef
32.
Walker CJ, Miranda MA, O’Hern MJ, McElroy JP, Coombes KR, Bundschuh R, et al. Patterns of CTCF and ZFHX3 mutation and associated outcomes in endometrial cancer. J Natl Cancer Inst. 2015;107.
33.
Katainen R, Dave K, Pitkanen E, Palin K, 0000000246216128 AO, Kivioja T, et al. CTCF/cohesin-binding sites are frequently mutated in cancer. Nat Genet. 2015;47:818–21.PubMedCrossRef
34.
Zou Y, Huang MZ, Liu FY, Yang BC, Wang LQ, Wang F, et al. Absence of and hotspot mutations in patients with various subtypes of ovarian carcinomas. Biomed Rep. 2015;3:33–7.PubMed
35.
Remeseiro S, Cuadrado A, Gomez-Lopez G, Pisano DG, Losada A. A unique role of cohesin-SA1 in gene regulation and development. EMBO J. 2012;31:2090–102.PubMedPubMedCentralCrossRef
36.
Monahan K, Rudnick ND, Kehayova PD, Pauli F, Newberry KM, Myers RM, et al. Role of CCCTC binding factor (CTCF) and cohesin in the generation of single-cell diversity of protocadherin-alpha gene expression. Proc Natl Acad Sci U S A. 2012;109:9125–30.PubMedPubMedCentralCrossRef
37.
Tan YP, Li S, Jiang XJ, Loh W, Foo YK, Loh CB, et al. Regulation of protocadherin gene expression by multiple neuron-restrictive silencer elements scattered in the gene cluster. Nucleic Acids Res. 2010;38:4985–97.PubMedPubMedCentralCrossRef
38.
Kehayova P, Monahan K, Chen W, Maniatis T. Regulatory elements required for the activation and repression of the protocadherin-alpha gene cluster. Proc Natl Acad Sci U S A. 2011;108:17195–200.PubMedPubMedCentralCrossRef
39.
Majumder S. REST in good times and bad: roles in tumor suppressor and oncogenic activities. Cell Cycle. 2006;5:1929–35.PubMedCrossRef
40.
Wagoner MP, Gunsalus KT, Schoenike B, Richardson AL, Friedl A, Roopra A. The transcription factor REST is lost in aggressive breast cancer. PLoS Genet. 2010;6:e1000979.PubMedPubMedCentralCrossRef
41.
42.
43.
Kawaguchi M, Toyama T, Kaneko R, Hirayama T, Kawamura Y, Yagi T. Relationship between DNA methylation states and transcription of individual isoforms encoded by the protocadherin-alpha gene cluster. J Biol Chem. 2008;283:12064–75.PubMedCrossRef
44.
Toyoda S, Kawaguchi M, Kobayashi T, Tarusawa E, Toyama T, Okano M, et al. Developmental epigenetic modification regulates stochastic expression of clustered protocadherin genes, generating single neuron diversity. Neuron. 2014;82:94–108.PubMedCrossRef
45.
Novak P, Jensen T, Oshiro MM, Watts GS, Kim CJ, Futscher BW. Agglomerative epigenetic aberrations are a common event in human breast cancer. Cancer Res. 2008;68:8616–25.PubMedCrossRef
46.
Miyamoto K, Fukutomi T, Akashi-Tanaka S, Hasegawa T, Asahara T, Sugimura T, et al. Identification of 20 genes aberrantly methylated in human breast cancers. Int J Cancer. 2005;116:407–14.PubMedCrossRef
47.
Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321:1801–6.PubMedPubMedCentralCrossRef
48.
Vincent A, Omura N, Hong SM, Jaffe A, Eshleman J, Goggins M. Genome-wide analysis of promoter methylation associated with gene expression profile in pancreatic adenocarcinoma. Clin Cancer Res. 2011;17:4341–54.PubMedPubMedCentralCrossRef
49.
Waha A, Guntner S, Huang TH, Yan PS, Arslan B, Pietsch T, et al. Epigenetic silencing of the protocadherin family member PCDH-gamma-A11 in astrocytomas. Neoplasia. 2005;7:193–9.PubMedPubMedCentralCrossRef
50.
Shi H, Guo J, Duff DJ, Rahmatpanah F, Chitima-Matsiga R, Al-Kuhlani M, et al. Discovery of novel epigenetic markers in non-Hodgkin’s lymphoma. Carcinogenesis. 2007;28:60–70.PubMedCrossRef
51.
Dallosso AR, Hancock AL, Szemes M, Moorwood K, Chilukamarri L, Tsai HH, et al. Frequent long-range epigenetic silencing of protocadherin gene clusters on chromosome 5q31 in Wilms’ tumor. PLoS Genet. 2009;5:e1000745.PubMedPubMedCentralCrossRef
52.
Dallosso AR, Oster B, Greenhough A, Thorsen K, Curry TJ, Owen C, et al. Long-range epigenetic silencing of chromosome 5q31 protocadherins is involved in early and late stages of colorectal tumorigenesis through modulation of oncogenic pathways. Oncogene. 2012;31:4409–19.PubMedPubMedCentralCrossRef
53.
Severson PL, Tokar EJ, Vrba L, Waalkes MP, Futscher BW. Agglomerates of aberrant DNA methylation are associated with toxicant-induced malignant transformation. Epilepsia. 2012;7:1238–48.
54.
Yu JS, Koujak S, Nagase S, Li CM, Su T, Wang X, et al. PCDH8, the human homolog of PAPC, is a candidate tumor suppressor of breast cancer. Oncogene. 2008;27:4657–65.PubMedPubMedCentralCrossRef
55.
Zhang D, Zhao W, Liao X, Bi T, Li H, Che X. Frequent silencing of protocadherin 8 by promoter methylation, a candidate tumor suppressor for human gastric cancer. Oncol Rep. 2012;28:1785–91.PubMed
56.
Lin YL, Wang YL, Ma JG, Li WP. Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer. J Exp Clin Cancer Res. 2014;33:68.PubMedPubMedCentralCrossRef
57.
Leshchenko VV, Kuo PY, Shaknovich R, Yang DT, Gellen T, Petrich A, et al. Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. Blood. 2010;116:1025–34.PubMedPubMedCentralCrossRef
58.
Yu B, Yang H, Zhang C, Wu Q, Shao Y, Zhang J, et al. High-resolution melting analysis of PCDH10 methylation levels in gastric, colorectal and pancreatic cancers. Neoplasma. 2010;57:247–52.PubMedCrossRef
59.
Yu J, Cheng YY, Tao Q, Cheung KF, Lam CN, Geng H, et al. Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer. Gastroenterology. 2009;136:640–51.e1.PubMedCrossRef
60.
Heitzer E, Artl M, Filipits M, Resel M, Graf R, Weissenbacher B, et al. Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC, and UCHL1. Mod Pathol. 2014;27:906–15.PubMedCrossRef
61.
Danese E, Minicozzi AM, Benati M, Montagnana M, Paviati E, Salvagno GL, et al. Epigenetic alteration: new insights moving from tissue to plasma—the example of PCDH10 promoter methylation in colorectal cancer. Br J Cancer. 2013;109:807–13.PubMedPubMedCentralCrossRef
62.
Deng J, Liang H, Ying G, Dong Q, Zhang L, Yu J, et al. Clinical significance of the methylated cytosine-phosphate-guanine sites of protocadherin-10 promoter for evaluating the prognosis of gastric cancer. J Am Coll Surg. 2014;219:904–13.PubMedCrossRef
63.
Ying J, Li H, Seng TJ, Langford C, Srivastava G, Tsao SW, et al. Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation. Oncogene. 2006;25:1070–80.PubMedCrossRef
64.
Narayan G, Scotto L, Neelakantan V, Kottoor SH, Wong AH, Loke SL, et al. Protocadherin PCDH10, involved in tumor progression, is a frequent and early target of promoter hypermethylation in cervical cancer. Genes Chromosom Cancer. 2009;48:983–92.PubMedPubMedCentralCrossRef
65.
Harada H, Miyamoto K, Yamashita Y, Taniyama K, Mihara K, Nishimura M, et al. Prognostic signature of protocadherin 10 methylation in curatively resected pathological stage I non-small-cell lung cancer. Cancer Med. 2015.
66.
Cheung HH, Lee TL, Davis AJ, Taft DH, Rennert OM, Chan WY. Genome-wide DNA methylation profiling reveals novel epigenetically regulated genes and non-coding RNAs in human testicular cancer. Br J Cancer. 2010;102:419–27.PubMedPubMedCentralCrossRef
67.
Ying J, Gao Z, Li H, Srivastava G, Murray PG, Goh HK, et al. Frequent epigenetic silencing of protocadherin 10 by methylation in multiple haematologic malignancies. Br J Haematol. 2007;136:829–32.PubMedCrossRef
68.
Haruki S, Imoto I, Kozaki K, Matsui T, Kawachi H, Komatsu S, et al. Frequent silencing of protocadherin 17, a candidate tumour suppressor for esophageal squamous cell carcinoma. Carcinogenesis. 2010;31:1027–36.PubMedCrossRef
69.
Hu X, Sui X, Li L, Huang X, Rong R, Su X, et al. Protocadherin 17 acts as a tumour suppressor inducing tumour cell apoptosis and autophagy, and is frequently methylated in gastric and colorectal cancers. J Pathol. 2013;229:62–73.PubMedCrossRef
70.
Imoto I, Izumi H, Yokoi S, Hosoda H, Shibata T, Hosoda F, et al. Frequent silencing of the candidate tumor suppressor PCDH20 by epigenetic mechanism in non-small-cell lung cancers. Cancer Res. 2006;66:4617–26.PubMedCrossRef
71.
Gendrel AV, Tang YA, Suzuki M, Godwin J, Nesterova TB, Greally JM, et al. Epigenetic functions of smchd1 repress gene clusters on the inactive X chromosome and on autosomes. Mol Cell Biol. 2013;33:3150–65.PubMedPubMedCentralCrossRef
72.
Chen K, Hu J, Moore DL, Liu R, Kessans SA, Breslin K, et al. Genome-wide binding and mechanistic analyses of Smchd1-mediated epigenetic regulation. Proc Natl Acad Sci U S A 2015.
73.
Leong HS, Chen K, Hu Y, Lee S, Corbin J, Pakusch M, et al. Epigenetic regulator Smchd1 functions as a tumor suppressor. Cancer Res. 2013;73:1591–9.PubMedCrossRef
74.
Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, et al. The COSMIC (catalogue of somatic mutations in cancer) database and website. Br J Cancer. 2004;91:355–8.PubMedPubMedCentral
75.
Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401–4.PubMedCrossRef
76.
Marambaud P, Wen PH, Dutt A, Shioi J, Takashima A, Siman R, et al. A CBP binding transcriptional repressor produced by the PS1/epsilon-cleavage of N-cadherin is inhibited by PS1 FAD mutations. Cell. 2003;114:635–45.PubMedCrossRef
77.
Maretzky T, Reiss K, Ludwig A, Buchholz J, Scholz F, Proksch E, et al. ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and beta-catenin translocation. Proc Natl Acad Sci U S A. 2005;102:9182–7.PubMedPubMedCentralCrossRef
78.
Marambaud P, Robakis NK. Genetic and molecular aspects of Alzheimer’s disease shed light on new mechanisms of transcriptional regulation. Genes Brain Behav. 2005;4:134–46.PubMedCrossRef
79.
Bonn S, Seeburg PH, Schwarz MK. Combinatorial expression of alpha- and gamma-protocadherins alters their presenilin-dependent processing. Mol Cell Biol. 2007;27:4121–32.PubMedPubMedCentralCrossRef
80.
Asad M, Wong MK, Tan TZ, Choolani M, Low J, Mori S, et al. FZD7 drives in vitro aggressiveness in Stem-A subtype of ovarian cancer via regulation of non-canonical Wnt/PCP pathway. Cell Death Dis. 2014;5:e1346.PubMedPubMedCentralCrossRef
81.
Wang C, Tao B, Li S, Li B, Wang X, Hu G, et al. Characterizing the role of PCDH9 in the regulation of glioma cell apoptosis and invasion. J Mol Neurosci. 2014;52:250–60.PubMedCrossRef
82.
Zhu P, Lv J, Yang Z, Guo L, Zhang L, Li M, et al. Protocadherin 9 inhibits epithelial-mesenchymal transition and cell migration through activating GSK-3beta in hepatocellular carcinoma. Biochem Biophys Res Commun. 2014;452:567–74.PubMedCrossRef
83.
Xu Y, Yang Z, Yuan H, Li Z, Li Y, Liu Q, et al. PCDH10 inhibits cell proliferation of multiple myeloma via the negative regulation of the Wnt/beta-catenin/BCL-9 signaling pathway. Oncol Rep. 2015;34:747–54.PubMed
84.
Jao TM, Tsai MH, Lio HY, Weng WT, Chen CC, Tzeng ST, et al. Protocadherin 10 suppresses tumorigenesis and metastasis in colorectal cancer and its genetic loss predicts adverse prognosis. Int J Cancer. 2014;135:2593–603.PubMedCrossRef
85.
Zhao Y, Yang Y, Trovik J, Sun K, Zhou L, Jiang P, et al. A novel wnt regulatory axis in endometrioid endometrial cancer. Cancer Res. 2014;74:5103–17.PubMedCrossRef
86.
Chen T, Long B, Ren G, Xiang T, Li L, Wang Z, et al. Protocadherin20 acts as a tumor suppressor gene: epigenetic inactivation in nasopharyngeal carcinoma. J Cell Biochem. 2015.
87.
Wu, JC, Wang FZ, Tsai ML, Lo CY, Badmaev V, Ho CT, et al. Se-Allylselenocysteine induces autophagy by modulating the AMPK/mTOR signaling pathway and epigenetic regulation of PCDH17 in human colorectal adenocarcinoma cells. Mol Nutr Food Res 2015.
88.
Dang Z, Shangguan J, Zhang C, Hu P, Ren Y, Lv Z, et al. Loss of protocadherin-17 (PCDH-17) promotes metastasis and invasion through hyperactivation of EGFR/MEK/ERK signaling pathway in hepatocellular carcinoma. Tumour Biol 2015.
89.
Chen MW, Vacherot F, De La Taille A, Gil-Diez-De-Medina S, Shen R, Friedman RA, et al. The emergence of protocadherin-PC expression during the acquisition of apoptosis-resistance by prostate cancer cells. Oncogene. 2002;21:7861–71.PubMedCrossRef
90.
Terry S, Maille P, Baaddi H, Kheuang L, Soyeux P, Nicolaiew N, et al. Cross modulation between the androgen receptor axis and protocadherin-PC in mediating neuroendocrine transdifferentiation and therapeutic resistance of prostate cancer. Neoplasia. 2013;15:761–72.PubMedPubMedCentralCrossRef
91.
Terry S, Queires L, Gil-Diez-de-Medina S, Chen MW, de la Taille A, Allory Y, et al. Protocadherin-PC promotes androgen-independent prostate cancer cell growth. Prostate. 2006;66:1100–13.PubMedPubMedCentralCrossRef
92.
Yang X, Chen MW, Terry S, Vacherot F, Chopin DK, Bemis DL, et al. A human- and male-specific protocadherin that acts through the wnt signaling pathway to induce neuroendocrine transdifferentiation of prostate cancer cells. Cancer Res. 2005;65:5263–71.PubMedCrossRef
93.
94.
Li AM, Tian AX, Zhang RX, Ge J, Sun X, Cao XC. Protocadherin-7 induces bone metastasis of breast cancer. Biochem Biophys Res Commun. 2013;436:486–90.PubMedCrossRef
95.
Du W, Liu X, Fan G, Zhao X, Sun Y, Wang T, et al. From cell membrane to the nucleus: an emerging role of E-cadherin in gene transcriptional regulation. J Cell Mol Med. 2014;18:1712–9.PubMedPubMedCentralCrossRef
96.
Han MH, Lin C, Meng S, Wang X. Proteomics analysis reveals overlapping functions of clustered protocadherins. Mol Cell Proteomics. 2010;9:71–83.PubMedCrossRef
97.
Wilker EW, van Vugt MA, Artim SA, Huang PH, Petersen CP, Reinhardt HC, et al. 14-3-3sigma controls mitotic translation to facilitate cytokinesis. Nature. 2007;446:329–32.PubMedCrossRef
98.
Urano T, Saito T, Tsukui T, Fujita M, Hosoi T, Muramatsu M, et al. Efp targets 14-3-3 sigma for proteolysis and promotes breast tumour growth. Nature. 2002;417:871–5.PubMedCrossRef
99.
Kohmura N, Senzaki K, Hamada S, Kai N, Yasuda R, Watanabe M, et al. Diversity revealed by a novel family of cadherins expressed in neurons at a synaptic complex. Neuron. 1998;20:1137–51.PubMedCrossRef
100.
101.
Vanhalst K, Kools P, Staes K, van Roy F, Redies C. Delta-Protocadherins: a gene family expressed differentially in the mouse brain. Cell Mol Life Sci. 2005;62:1247–59.PubMedCrossRef
102.
Heggem MA, Bradley RS. The cytoplasmic domain of Xenopus NF-protocadherin interacts with TAF1/set. Dev Cell. 2003;4:419–29.PubMedCrossRef
103.
Yasuda S, Tanaka H, Sugiura H, Okamura K, Sakaguchi T, Tran U, et al. Activity-induced protocadherin arcadlin regulates dendritic spine number by triggering N-cadherin endocytosis via TAO2beta and p38 MAP kinases. Neuron. 2007;56:456–71.PubMedPubMedCentralCrossRef
104.
Nakao S, Platek A, Hirano S, Takeichi M. Contact-dependent promotion of cell migration by the OL-protocadherin-Nap1 interaction. J Cell Biol. 2008;182:395–410.PubMedPubMedCentralCrossRef
105.
106.
Homayouni R, Rice DS, Curran T. Disabled-1 interacts with a novel developmentally regulated protocadherin. Biochem Biophys Res Commun. 2001;289:539–47.PubMedCrossRef
107.
Borrell V, Pujadas L, Simo S, Dura D, Sole M, Cooper JA, et al. Reelin and mDab1 regulate the development of hippocampal connections. Mol Cell Neurosci. 2007;36:158–73.PubMedCrossRef
108.
Kahr I, Vandepoele K, van Roy F. Delta-protocadherins in health and disease. Prog Mol Biol Transl Sci. 2013;116:169–92.PubMedCrossRef
109.
Kietzmann A, Wang Y, Weber D, Steinbeisser H. Xenopus paraxial protocadherin inhibits Wnt/beta-catenin signalling via casein kinase 2beta. EMBO Rep. 2012;13:129–34.PubMedCrossRef
110.
Kai M, Ueno N, Kinoshita N. Phosphorylation-dependent ubiquitination of paraxial protocadherin (PAPC) controls gastrulation cell movements. PLoS One. 2015;10:e0115111.PubMedPubMedCentralCrossRef
111.
Schalm SS, Ballif BA, Buchanan SM, Phillips GR, Maniatis T. Phosphorylation of protocadherin proteins by the receptor tyrosine kinase Ret. Proc Natl Acad Sci U S A. 2010;107:13894–9.PubMedPubMedCentralCrossRef
112.
Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, et al. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science. 1995;267:381–3.PubMedCrossRef
113.
Fernandez-Sanchez ME, Barbier S, Whitehead J, Bealle G, Michel A, Latorre-Ossa H, et al. Mechanical induction of the tumorigenic beta-catenin pathway by tumour growth pressure. Nature. 2015;523:92–5.PubMedCrossRef
114.
Faura TG, Vandepoele K, Brouwer U, Koning H, Elderman RM, Hackett TL, et al. Protocadherin-1 binds to SMAD3 and suppresses TGFbeta1-induced gene transcription. Am J Physiol Lung Cell Mol Physiol. 2015:ajplung.00346.2014.
115.
Wu C, Niu L, Yan Z, Wang C, Liu N, Dai Y, et al. Pcdh11x negatively regulates dendritic branching. J Mol Neurosci. 2015;56:822–8.PubMedCrossRef
116.
117.
Chen X, Gumbiner BM. Paraxial protocadherin mediates cell sorting and tissue morphogenesis by regulating C-cadherin adhesion activity. J Cell Biol. 2006;174:301–13.PubMedPubMedCentralCrossRef
118.
Kazmierczak P, Sakaguchi H, Tokita J, Wilson-Kubalek EM, Milligan RA, Muller U, et al. Cadherin 23 and protocadherin 15 interact to form tip-link filaments in sensory hair cells. Nature. 2007;449:87–91.PubMedCrossRef
119.
120.
Kraft B, Berger CD, Wallkamm V, Steinbeisser H, Wedlich D. Wnt-11 and Fz7 reduce cell adhesion in convergent extension by sequestration of PAPC and C-cadherin. J Cell Biol. 2012;198:695–709.PubMedPubMedCentralCrossRef
121.
Jung B, Kohler A, Schambony A, Wedlich D. PAPC and the Wnt5a/Ror2 pathway control the invagination of the otic placode in Xenopus. BMC Dev Biol. 2011;11:36.PubMedPubMedCentralCrossRef
122.
Himmelreich N, Kaufmann, LT, Steinbeisser H, Korner C, Thiel C. Lack of phosphomannomutase 2 affects Xenopus laevis morphogenesis and the non-canonical Wnt5a/Ror2 signalling. J Inherit Metab Dis. 2015.
123.
Kozu Y, Gon Y, Maruoka S, Kazumichi K, Sekiyama A, Kishi H, et al. Protocadherin-1 is a glucocorticoid-responsive critical regulator of airway epithelial barrier function. BMC Pulm Med. 2015;15:80.PubMedPubMedCentralCrossRef
124.
125.
Suo L, Lu H, Ying G, Capecchi MR, Wu Q. Protocadherin clusters and cell adhesion kinase regulate dendrite complexity through Rho GTPase. J Mol Cell Biol. 2012;4:362–76.PubMedCrossRef
126.
Zhang X, Chattopadhyay A, Ji QS, Owen JD, Ruest PJ, Carpenter G, et al. Focal adhesion kinase promotes phospholipase C-gamma1 activity. Proc Natl Acad Sci U S A. 1999;96:9021–6.PubMedPubMedCentralCrossRef
127.
Tvorogov D, Wang XJ, Zent R, Carpenter G. Integrin-dependent PLC-gamma1 phosphorylation mediates fibronectin-dependent adhesion. J Cell Sci. 2005;118:601–10.PubMedCrossRef
128.
Heemskerk FM, Chen HC, Huang FL. Protein kinase C phosphorylates Ser152, Ser156 and Ser163 but not Ser160 of MARCKS in rat brain. Biochem Biophys Res Commun. 1993;190:236–41.PubMedCrossRef
129.
Li H, Chen G, Zhou B, Duan S. Actin filament assembly by myristoylated alanine-rich C kinase substrate-phosphatidylinositol-4,5-diphosphate signaling is critical for dendrite branching. Mol Biol Cell. 2008;19:4804–13.PubMedPubMedCentralCrossRef
130.
Keeler AB, Schreiner D, Weiner JA, Protein Kinase C. Phosphorylation of a gamma-protocadherin C-terminal lipid binding domain regulates focal adhesion kinase inhibition and dendrite arborization. J Biol Chem. 2015;290:20674–86.PubMedPubMedCentralCrossRef
131.
Biswas S, Emond MR, Duy PQ, Hao lT, Beattie CE, Jontes JD. Protocadherin-18b interacts with Nap1 to control motor axon growth and arborization in zebrafish. Mol Biol Cell. 2014;25:633–42.PubMedPubMedCentralCrossRef
132.
Takenawa T, Suetsugu S. The WASP-WAVE protein network: connecting the membrane to the cytoskeleton. Nat Rev Mol Cell Biol. 2007;8:37–48.PubMedCrossRef
133.
Kurisu S, Takenawa T. WASP and WAVE family proteins: friends or foes in cancer invasion. Cancer Sci. 2010;101:2093–104.PubMedCrossRef
134.
Hayashi S, Inoue Y, Kiyonari H, Abe T, Misaki K, Moriguchi H, et al. Protocadherin-17 mediates collective axon extension by recruiting actin regulator complexes to interaxonal contacts. Dev Cell. 2014;30:673–87.PubMedCrossRef
135.
Hoshina N, Tanimura A, Yamasaki M, Inoue T, Fukabori R, Kuroda T, et al. Protocadherin 17 regulates presynaptic assembly in topographic corticobasal ganglia circuits. Neuron. 2013;78:839–54.PubMedCrossRef
136.
Brigidi GS, Bamji SX. Cadherin-catenin adhesion complexes at the synapse. Curr Opin Neurobiol. 2011;21:208–14.PubMedCrossRef
137.
Biswas S, Emond MR, Jontes JD. Protocadherin-19 and N-cadherin interact to control cell movements during anterior neurulation. J Cell Biol. 2010;191:1029–41.PubMedPubMedCentralCrossRef
138.
Morrow EM, Yoo SY, Flavell SW, Kim TK, Lin Y, Hill RS, et al. Identifying autism loci and genes by tracing recent shared ancestry. Science. 2008;321:218–23.PubMedPubMedCentralCrossRef
139.
Tsai NP, Wilkerson JR, Guo W, Maksimova MA, DeMartino GN, Cowan CW, et al. Multiple autism-linked genes mediate synapse elimination via proteasomal degradation of a synaptic scaffold PSD-95. Cell. 2012;151:1581–94.PubMedPubMedCentralCrossRef
140.
Bassermann F, Eichner R, Pagano M. The ubiquitin proteasome system - implications for cell cycle control and the targeted treatment of cancer. Biochim Biophys Acta. 2014;1843:150–62.PubMedCrossRef
141.
Schaefer A, Nethe M, Hordijk PL. Ubiquitin links to cytoskeletal dynamics, cell adhesion and migration. Biochem J. 2012;442:13–25.PubMedCrossRef
142.
Haas IG, Frank M, Veron N, Kemler R. Presenilin-dependent processing and nuclear function of gamma-protocadherins. J Biol Chem. 2005;280:9313–9.PubMedCrossRef
143.
Trimarchi T, Bilal E, Ntziachristos P, Fabbri G, Dalla-Favera R, Tsirigos A, et al. Genome-wide mapping and characterization of Notch-regulated long noncoding RNAs in acute leukemia. Cell. 2014;158:593–606.PubMedPubMedCentralCrossRef
144.
145.
146.
Colomer J, Means AR. Physiological roles of the Ca2+/CaM-dependent protein kinase cascade in health and disease. Subcell Biochem. 2007;45:169–214.PubMedCrossRef
147.
Gardner HP, Ha SI, Reynolds C, Chodosh LA. The caM kinase, Pnck, is spatially and temporally regulated during murine mammary gland development and may identify an epithelial cell subtype involved in breast cancer. Cancer Res. 2000;60:5571–7.PubMed
148.
Takai N, Ueda T, Nasu K, Yamashita S, Toyofuku M, Narahara H. Targeting calcium/calmodulin-dependence kinase I and II as a potential anti-proliferation remedy for endometrial carcinomas. Cancer Lett. 2009;277:235–43.PubMedCrossRef
149.
Onouchi T, Kishino-Kaneko Y, Kameshita I, Ishida A, Sueyoshi N. Regulation of Ca/calmodulin-dependent protein kinase phosphatase (CaMKP/PPM1F) by protocadherin-gammaC5 (Pcdh-gammaC5). Arch Biochem Biophys 2015.
Metadata
Title
Aberrant expression and functions of protocadherins in human malignant tumors
Authors
Ming Shan
Yonghui Su
Wenli Kang
Ruixin Gao
Xiaobo Li
Guoqiang Zhang
Publication date
01-10-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 10/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-5169-9

Other articles of this Issue 10/2016

Tumor Biology 10/2016 Go to the issue

Original Article

DNA repair pathways to regulate response to chemoradiotherapy in patients with locally advanced head and neck cancer

Original Article

Violacein induces death of RAS-mutated metastatic melanoma by impairing autophagy process

Original Article

Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value

Original Article

MiR-384 regulated IRS1 expression and suppressed cell proliferation of human hepatocellular carcinoma

Original Article

Clinicopathological and prognostic significance of Yes-associated protein expression in hepatocellular carcinoma and hepatic cholangiocarcinoma

Original Article

miR-101 sensitizes K562 cell line to imatinib through Jak2 downregulation and inhibition of NF-κB target genes

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits